NIV-NAVA in Infants With Severe Bronchiolitis, a Pilot Multicenter Randomized Controlled Trial (NAVIGATE)
Non-invasive Ventilation With NAVA in Infants With Severe Bronchiolitis. A Multicenter Pilot Open Label Pragmatic Randomized Controlled Trial (NAVIGATE Trial)
Severe bronchiolitis is a common lung infection in babies that can cause serious breathing problems and often leads to hospitalization in pediatric intensive care units (PICUs). Many infants need special breathing support, usually through non-invasive methods like high-flow oxygen or continuous airway pressure. However, these methods don't always work, and about one in four infants end up needing a breathing tube (intubation), which comes with more risks and a longer recovery.
A newer breathing support method called NIV-NAVA (non-invasive ventilation with neurally adjusted ventilatory assist) may help. It uses signals from the baby's diaphragm to adjust the support in real-time, making breathing easier and possibly reducing the need for intubation. While early results are promising, no high-quality clinical trial has yet tested if NIV-NAVA is better than standard non-invasive support.
This study is a pilot trial - a small-scale version of a larger future study - happening in four PICUs across Canada. It will include 90 babies under 2 years old with severe bronchiolitis who need more support than standard methods provide. Half will receive NIV-NAVA, and half will receive the usual care.
The main goal of this pilot is to check if a larger trial is doable: Can we recruit enough babies? Can the PICU teams stick to the treatment plan? Can we collect the right information? The full study will eventually look at whether NIV-NAVA really lowers the number of babies who need intubation and improves recovery.
This research is led by a team of pediatric experts and could pave the way for better care for thousands of infants with severe breathing problems.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Goal(s) / Research Aims The primary objective of this multicenter pilot RCT is to determine the feasibility of a definitive multicenter RCT that will evaluate whether NIV-NAVA is superior to conventional NIV in infants with severe bronchiolitis who are not adequately supported by HFNC or CPAP. The primary hypothesis is that the pilot RCT will confirm the feasibility of the final trial.
Methods / Approaches This is an investigator-led, multicenter, randomized, controlled, open-label, pragmatic pilot trial conducted in four Canadian pediatric intensive care units (PICUs) with varying levels of experience with NIV-NAVA, supported by the Canadian Critical Care Trials Group (CCCTG).
Ninety infants younger than 2 years old who are admitted to the PICU with a clinical diagnosis of bronchiolitis, who require NIV support greater than CPAP/HFNC, and who have no exclusion criteria will be randomized 1:1 between NIV-NAVA and conventional NIV management.
The pilot trial's feasibility outcomes are the recruitment rate (the primary outcome), adherence to the intervention, and completion of the definitive trial's outcome measures. The primary outcome of the future definitive RCT is the intubation rate. Secondary outcomes will include respiratory distress evolution, comfort, duration of ventilatory support, PICU and hospital length of stay, nutrition and sedation, complication rates, post-PICU functional outcomes, carbon footprint, and cost-effectiveness analysis.
Expertise. An experienced, multidisciplinary team of senior, mid, and early career clinician scientists with unique expertise in pediatric NIV, trial methodology, pediatric respirology, and PICU research is leading this project.
Expected Outcomes. We expect this pilot trial to confirm the feasibility of a definitive trial on NIV-NAVA in severe bronchiolitis. As the first RCT in this understudied field, it will provide much-needed evidence on the most effective strategy for reducing intubation rates in infants with severe bronchiolitis.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Guillaume Emeriaud, MD PhD
- 電話番号:5143454708
- メール:guillaume.emeriaud@umontreal.ca
研究連絡先のバックアップ
- 名前:Lucy Clayton, MSc
- メール:lucy.clayton.hsj@ssss.gouv.qc.ca
研究場所
-
-
Alberta
-
Calgary、Alberta、カナダ
- Alberta Children's Hospital
-
コンタクト:
- Laurie Lee, NPS PhD
- 電話番号:4032206546
- メール:laurie.lee@ucalgary.ca
-
-
Ontario
-
Ottawa、Ontario、カナダ
- CHEO
-
コンタクト:
- Dayre McNally, MD
- 電話番号:6137377600
- メール:dmcnally@cheo.on.ca
-
-
Quebec
-
Montreal、Quebec、カナダ
- Montreal Children's Hospital
-
コンタクト:
- Patricia Fontela, MD PhD
- 電話番号:22855 5144124400
- メール:patricia.fontela.med@ssss.gouv.qc.ca
-
Montreal、Quebec、カナダ
- CHU Sainte Justine
-
コンタクト:
- Guillaume Emeriaud, MD PhD
- 電話番号:5143454708
- メール:guillaume.emeriaud@umontreal.ca
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Infants younger than 2 years old
- admitted to the PICU (or managed by the PICU team while awaiting PICU admission)
- with a clinical diagnosis of bronchiolitis according to the treating team
- requiring NIV support higher than CPAP/HFNC according to the treating team, a criteria present for less than 8 hours.
Exclusion Criteria:
- imminent intubation criteria
- refusal by the physician in charge
- chronic home ventilation
- hemodynamic instability requiring vasopressors
- contraindication to NIV or to gastric tube insertion
- patients in whom a limitation of life-support treatment is considered
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
アクティブコンパレータ:NIV-NAVA arm
Installation of an Edi catheter. Ventilation with NIV-NAVA as long as a bi-level NIV support is needed. |
Non-invasive support using NAVA technology |
|
介入なし:Control arm (usual care)
Ventilation according to the clinical team. No NAVA ventilation allowed. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recruitment rate
時間枠:from initiation to the end of the 6-month study enrolment period
|
% of eligible patients (identified by screening) who are included in the study at each site and overall |
from initiation to the end of the 6-month study enrolment period
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
adherence to the intervention
時間枠:during the NIV support period, starting from randomization to the end of the bi-level support NIV (=no NIV-NAVA or BIPAP for at least 48 hours), up to a maximum of 28 days
|
In the NAVA arm : % of patients who receive at least 2 hours of NIV-NAVA support, within 2 hours after randomization. In control arm: absence of NAVA use |
during the NIV support period, starting from randomization to the end of the bi-level support NIV (=no NIV-NAVA or BIPAP for at least 48 hours), up to a maximum of 28 days
|
|
completion of the definitive trial outcomes
時間枠:from initiation to the end of the 6-month study enrolment period
|
completion of the definitive trial outcomes : measurement of intubation rate, duration of ventilatory support, length of PICU and hospital stays |
from initiation to the end of the 6-month study enrolment period
|
|
Evolution of the respiratory distress mWCAS score
時間枠:at randomization, and after 2, 6, and 24 hours
|
Evolution of mWCAS |
at randomization, and after 2, 6, and 24 hours
|
|
Evolution of the respiratory distress ROX-HR score
時間枠:at randomization, and after 2, 6, and 24 hours
|
Evolution of ROX-HR scores |
at randomization, and after 2, 6, and 24 hours
|
|
Evolution of the comfort score
時間枠:at randomization, and after 2, 6, and 24 hours
|
Evolution of the comfort score (FLACC) |
at randomization, and after 2, 6, and 24 hours
|
|
Capacity to assess the evolution at 3 months post PICU
時間枠:3 months post PICU discharge
|
Percentage of patients with assessment of PICS-p at 3 months post discharge |
3 months post PICU discharge
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Guillaume Emeriaud, MD PhD、CHU Sainte Justine, Université de Montréal
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- MP-21-2027-10447
- 583747 (その他の助成金/資金番号:CIHR)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
This is a pilot study. If the pilot shows feasibility of a larger trial with no change in the protocol, we may continue the trial with the same protocol and enroll the subjects from the pilot within the larger trial (Vanguard).
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。